A carregar...
A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment
Sitagliptin is the first dipeptidylpeptidase-4 inhibitor to be used in the management of type 2 diabetes. It is widely used as an add-on therapy to ongoing management or as monotherapy where it is deemed necessary. It has been found to be beneficial in improving β-cell function and glycemic control,...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3770622/ https://ncbi.nlm.nih.gov/pubmed/24039399 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S32331 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|